Xenon Pharmaceuticals Inc (XENE-Q) Analyst Research & Price Targets - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Current Target Price

High Target Price

Mean Target Price

Low Target Price

Median Target Price

Earnings Estimates

	Current Qtr03/2024	Next Qtr06/2024	Fiscal Yr12/2024	Fiscal Yr12/2025
Average Estimate	-0.69	-0.72	-3.04	-3.51
Number of Estimates	8	7	11	10
High Estimate	-0.63	-0.65	-2.52	-2.10
Low Estimate	-0.77	-0.82	-3.54	-4.47
Prior Year	-0.63	-0.72	-2.73	-3.04
Growth Rate Est. (year over year)	-9.52%	unch	-11.36%	-15.46%

Earnings History - Surprises*

	Qtr Ending12/2023	Qtr Ending09/2023	Qtr Ending06/2023	Qtr Ending03/2023
Reported	$-0.64	$-0.73	$-0.72	$-0.63
Estimate	$-0.76	$-0.75	$-0.69	$-0.62
Difference	+0.12	+0.02	-0.03	-0.01
Surprise	+15.79%	+2.67%	-4.35%	-1.61%

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.83

3 Mths Ago18

4.83

2 Mths Ago18

4.83

1 Mth Ago18

4.83

Current18

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	18	18	18	18
	15 3	15 3	15 3	15 3
Holds	0	0	0	0

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy

Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders

The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market

Fiera Capital’s largest shareholder looks to sell stake in company

The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide

The close: Stocks higher as investors digest earnings

The close: Stocks higher with major corporate earnings on tap

If pension funds can’t see the case for investing in Canada, why should you?